New Mānuka Honey: A Natural Antibiotic Against Drug-Resistant Bacteria
A groundbreaking collaboration between Aston University and New Zealand-based Mānuka honey producer Comvita has led to a new formulation that could revolutionize the fight against drug-resistant bacteria. The joint research effort, spanning three years, has resulted in a novel patent application for a Mānuka honey-based solution that outperforms the honey itself in combating bacterial infections.
The unique antimicrobial properties of Mānuka honey have been harnessed to address the global health crisis of antimicrobial resistance (AMR). This new formulation demonstrates remarkable efficacy against various drug-resistant bacterial strains, including MRSA, a major cause of hospital infections and deaths worldwide. The research highlights the potential of Mānuka honey as a natural, effective alternative to traditional antibiotics, which are increasingly losing their effectiveness due to AMR.
The announcement coincides with World Antimicrobial Resistance Awareness Week, emphasizing the importance of international scientific collaborations. New Zealand and the UK are committed to developing innovative solutions to this critical global issue. AMR is a significant public health concern, with the World Health Organization (WHO) ranking it among the top 10 global health challenges, potentially causing up to 10 million deaths annually by 2050.
In New Zealand, Māori and Pacific people are disproportionately affected by infection-related hospitalizations, making them more susceptible to antibiotic-resistant infections. Similarly, in the UK, AMR is classified as a chronic risk, contributing to 35,200 deaths annually. The new Mānuka honey formulation offers a promising natural solution to this growing problem.
Dr. Jonathan Cox, a senior lecturer in microbiology at Aston University, expressed enthusiasm about the findings: "Antibiotic-resistant infections, such as Mycobacterium abscessus, are incredibly challenging to treat, and new therapeutic options are urgently needed. Our research demonstrates that Mānuka honey, both in its pure form and as a novel formulation, and in combination with existing antibiotics, holds remarkable potential in tackling AMR. Filing this patent is a significant step towards translating our laboratory discoveries into practical treatments that can make a real difference for patients worldwide."
Dr. Jackie Evans, Comvita's chief science officer, added, "This patent marks a significant milestone in our mission to advance the science of Mānuka honey and unlock its full potential in global health. Our collaboration with Dr. Cox exemplifies the synergy between science and nature, and it serves as a model for how industry and academia worldwide can work together to tackle complex health challenges. As AMR continues to rise globally, the demand for safe, natural, and effective alternatives has never been more critical. We are proud to lead research that could one day contribute to better health outcomes for communities everywhere."
The collaboration between Comvita and Aston University is a testament to the power of international research partnerships. Her Excellency Iona Thomas, the British High Commissioner to New Zealand, praised this partnership, stating, "This collaboration between Comvita and Aston University is a prime example of the strength of UK-New Zealand research partnerships. AMR is one of the most pressing health challenges of our time, and it will require innovative, cross-border thinking to solve it. Seeing world-class researchers and industry leaders come together to advance a nature-based solution is exactly the kind of impact our countries can deliver when we work in harmony."
This groundbreaking research highlights the potential of natural remedies like Mānuka honey in the fight against drug-resistant bacteria, offering a glimmer of hope in the battle against AMR.
